Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Adagrasib

FDA-approved product (tablet, oral), marketed as Krazati.

Registered studies
40
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Adagrasib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

40registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Adagrasib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Adagrasib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

    NCT06039384 · start 2023-12-28

    Registered record
    Registry ID
    NCT06039384
    Conditions
    Advanced Solid Tumors
    Interventions
    INCB099280; adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-12-28
    Completion
    2025-07-11
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionINCB099280; adagrasib
    PhasePhase 1
    Registry statusTerminated

  • Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

    NCT05722327 · start 2023-12-06

    Registered record
    Registry ID
    NCT05722327
    Conditions
    Colon Cancer; Colorectal Cancer
    Interventions
    MRTX849; Irinotecan; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-12-06
    Completion
    2027-09-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer; Colorectal Cancer
    InterventionMRTX849; Irinotecan; Cetuximab
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

    NCT06024174 · start 2023-11-09

    Registered record
    Registry ID
    NCT06024174
    Conditions
    Advanced Solid Tumors
    Interventions
    BMS-986466; Adagrasib; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2023-11-09
    Completion
    2024-05-13
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionBMS-986466; Adagrasib; Cetuximab
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    NCT06026410 · start 2023-10-18

    Registered record
    Registry ID
    NCT06026410
    Conditions
    Solid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Clear Cell Renal Cell Carcinoma (ccRCC); Renal Cell Carcinoma (Kidney Cancer); Non Clear Cell Renal Cell Carcinoma (nccRCC)
    Interventions
    Darlifarnib; Cabozantinib; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-10-18
    Completion
    2027-04
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors With HRAS Alterations; Non Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC) +3 more
    InterventionDarlifarnib; Cabozantinib; Adagrasib
    PhasePhase 1
    Registry statusRecruiting

  • Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

    NCT05840510 · start 2023-08-07

    Registered record
    Registry ID
    NCT05840510
    Conditions
    Solid Tumor, Adult; NSCLC; Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
    Interventions
    Adagrasib; nab-Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2023-08-07
    Completion
    2024-12-27
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor, Adult; NSCLC; Advanced Cancer; Metastatic Cancer +1 more
    InterventionAdagrasib; nab-Sirolimus
    PhasePhase 1
    Registry statusTerminated

  • A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

    NCT05924152 · start 2023-06-29

    Registered record
    Registry ID
    NCT05924152
    Conditions
    Healthy Adults
    Interventions
    Adagrasib; Eltrombopag + adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-06-29
    Completion
    2023-08-17
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionAdagrasib; Eltrombopag + adagrasib
    PhasePhase 1
    Registry statusCompleted

  • Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

    NCT05673187 · start 2023-06-12

    Registered record
    Registry ID
    NCT05673187
    Conditions
    NSCLC Stage IV; KRAS P.G12C
    Interventions
    Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-06-12
    Completion
    2026-12
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Stage IV; KRAS P.G12C
    InterventionAdagrasib
    PhasePhase 2
    Registry statusActive not recruiting

  • A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

    NCT05868356 · start 2023-06-01

    Registered record
    Registry ID
    NCT05868356
    Conditions
    Healthy Adults
    Interventions
    Treatment A; Treatment B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2023-08-07
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionTreatment A; Treatment B
    PhasePhase 1
    Registry statusCompleted

  • Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

    NCT05634525 · start 2023-05-03

    Registered record
    Registry ID
    NCT05634525
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    MRTX849
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-05-03
    Completion
    2025-07-21
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionMRTX849
    PhasePhase 1
    Registry statusWithdrawn

  • A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations

    NCT05848843 · start 2023-04-25

    Registered record
    Registry ID
    NCT05848843
    Conditions
    Lung Cancer; Gastro-intestinal Cancer
    Interventions
    Durvalumab; Adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2023-04-25
    Completion
    2024-01-16
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Gastro-intestinal Cancer
    InterventionDurvalumab; Adagrasib
    PhasePhase 1
    Registry statusWithdrawn

  • Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

    NCT05472623 · start 2023-03-21

    Registered record
    Registry ID
    NCT05472623
    Conditions
    Resectable Non-Small Cell Lung Cancer
    Interventions
    Adagrasib; Adagrasib/Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-03-21
    Completion
    2025-09-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResectable Non-Small Cell Lung Cancer
    InterventionAdagrasib; Adagrasib/Nivolumab
    PhasePhase 2
    Registry statusWithdrawn

  • A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

    NCT05578092 · start 2022-12-02

    Registered record
    Registry ID
    NCT05578092
    Conditions
    Solid Tumor; Advanced Solid Tumor; Non Small Cell Lung Cancer; Colo-rectal Cancer
    Interventions
    MRTX0902; MRTX849
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-12-02
    Completion
    2026-02-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Advanced Solid Tumor; Non Small Cell Lung Cancer; Colo-rectal Cancer
    InterventionMRTX0902; MRTX849
    PhasePhase 1
    Registry statusTerminated

  • Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

    NCT05609578 · start 2022-11-22

    Registered record
    Registry ID
    NCT05609578
    Conditions
    Advanced NSCLC; Metastatic Lung Cancer
    Interventions
    Adagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-11-22
    Completion
    2026-12-01
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced NSCLC; Metastatic Lung Cancer
    InterventionAdagrasib oral dose of 400 mg twice daily tablets; Pembrolizumab; Chemotherapy: Pemetrexed; Cisplatin/Carboplatin
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

    NCT05375994 · start 2022-08-01

    Registered record
    Registry ID
    NCT05375994
    Conditions
    Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant Neoplasm of Lung; Malignant Neoplastic Disease
    Interventions
    avutometinib (VS-6766) and adagrasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2026-06-15
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer +2 more
    Interventionavutometinib (VS-6766) and adagrasib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

    NCT05263986 · start 2022-05-30

    Registered record
    Registry ID
    NCT05263986
    Conditions
    Advanced or Metastatic Solid Tumor
    Interventions
    MRTX849
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-05-30
    Completion
    2023-10-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced or Metastatic Solid Tumor
    InterventionMRTX849
    PhasePhase 1
    Registry statusUnknown